Go Pro
→ Buy this stock today (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$48.04
-2.9%		$46.51
$15.80
▼
$94.90
$3.52B-1.5547,729 shs407,565 shs
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
$31.78
-2.3%		$31.82
$23.22
▼
$37.15
$61.28M0.4125,489 shs18,934 shs
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
$25.40
-1.8%		$25.17
$21.70
▼
$27.28
$5.08M0.372,058 shs1,659 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-2.89%-2.20%-7.83%+13.81%+169.43%
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
-2.28%-2.16%-1.88%+1.40%+27.94%
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
-1.78%-0.97%-0.78%+3.13%+10.82%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$48.04
-2.9%		$46.51
$15.80
▼
$94.90
$3.52B-1.5547,729 shs407,565 shs
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
$31.78
-2.3%		$31.82
$23.22
▼
$37.15
$61.28M0.4125,489 shs18,934 shs
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
$25.40
-1.8%		$25.17
$21.70
▼
$27.28
$5.08M0.372,058 shs1,659 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-2.89%-2.20%-7.83%+13.81%+169.43%
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
-2.28%-2.16%-1.88%+1.40%+27.94%
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
-1.78%-0.97%-0.78%+3.13%+10.82%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.89
Moderate Buy$110.55130.11% Upside
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
2.58
Moderate Buy$31.78N/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
2.58
Moderate Buy$25.40N/A

Current Analyst Ratings Breakdown

Latest OZEM, THNR, and GPCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/11/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$100.00 ➝ $70.00
(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$24.99 per shareN/A
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/AN/AN/AN/AN/AN/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/AN/A22.34N/AN/AN/AN/AN/AN/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/A24.31N/AN/AN/AN/AN/AN/A

Latest OZEM, THNR, and GPCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.39N/AN/AN/AN/AN/A
5/7/2026Q1 2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
$0.050.16%N/AN/AN/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
$0.220.87%N/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
26.16
26.16
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/AN/AN/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/A

Insider Ownership

CompanyInsider Ownership
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
5.50%
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13671.08 million67.17 millionOptionable
Roundhill GLP-1 & Weight Loss ETF stock logo
OZEM
Roundhill GLP-1 & Weight Loss ETF
N/A1.93 millionN/AN/A
Amplify Weight Loss Drug & Treatment ETF stock logo
THNR
Amplify Weight Loss Drug & Treatment ETF
N/A200,000N/AN/A

Recent News About These Companies

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Shares Up 0.3% - Still a Buy?
July 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30911578
Inside THNR: A Leaner Approach to Weight Loss Investing
July 7, 2026  |  etftrends.comE
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
July 1, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2945928/weight-loss-etfs-poised-to-rally-as-medicare-greenlights-glp-1-coverage?cid=cs-stocknewsapi-ft-etf_news_and_commentary-2945928
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
June 11, 2026  |  etftrends.comE
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
June 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2935370/inside-the-glp-1-boom-etf-picks-for-the-obesity-drug-market?cid=cs-stocknewsapi-ft-etf_news_and_commentary-2935370
LLY Clears Major Obesity Trial: Get Exposure in THNR
May 21, 2026  |  etftrends.comE
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
May 19, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2923643/glp-1-drug-giants-race-to-go-global-with-their-obesity-pills-etfs-to-gain?cid=cs-stocknewsapi-ft-etf_news_and_commentary-2923643
3 Ways to Invest in the Growing GLP-1 Weight Loss Market (THNR)
...
April 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/stock-ideas/3-ways-to-invest-in-the-growing-glp-1-weight-loss-market/
Weight Loss ETF THNR Reweights Its Index: What's Up & Down
March 25, 2026  |  etftrends.comE
Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Update
March 13, 2026  |  defenseworld.netD
ETFs tied to HIMS gain attention as the telehealth stock spikes
March 9, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/etfs-tied-to-hims-gain-attention-as-the-telehealth-stock-spikes/ar-AA1XPuL3
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
February 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2828794/healthcare-etfs-to-watch-as-novo-nordisk-tumbles-on-poor-sales-outlook?cid=cs-stocknewsapi-ft-etf_news_and_commentary-2828794
New Year, New Strategy: Navigating Weight Loss ETFs
January 12, 2026  |  etftrends.comE
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs
September 18, 2025  |  benzinga.comhttps://www.benzinga.com/etfs/sector-etfs/25/09/47744073/hims-hers-eli-lilly-novo-nordisk-face-fda-scrutiny-what-it-means-for-weight-loss-etfs?utm_source=snapi
Weight Loss Drug ETF (THNR) Hits New 52-Week High
June 2, 2025  |  zacks.comhttps://www.zacks.com/stock/news/2480003/weight-loss-drug-etf-thnr-hits-new-52-week-high?cid=cs-stocknewsapi-ft-etf_news_and_commentary-2480003
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs
January 17, 2025  |  etftrends.comE
Disruptive Theme of the Week – Breakthroughs in Medicine
November 21, 2024  |  etftrends.comE
Amplify ETFs Hits $10 Billion in Assets Amid New ETF Launches
October 29, 2024  |  etftrends.comE
Tap the Weight-Loss Drug Market With These ETFs
September 18, 2024  |  zacks.comhttps://www.zacks.com/stock/news/2337974/tap-the-weight-loss-drug-market-with-these-etfs?cid=cs-stocknewsapi-ft-etf_news_and_commentary-2337974
Disruptive Theme of the Week: Playing Defense
August 14, 2024  |  etftrends.comE
ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment
July 22, 2024  |  zacks.comhttps://www.zacks.com/stock/news/2306321/etfs-in-focus-as-competition-heats-up-in-weight-loss-drug-segment?cid=cs-stocknewsapi-ft-etf_news_and_commentary-2306321

New MarketBeat Followers Over Time

Media Sentiment Over Time

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$48.04 -1.43 (-2.89%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$48.07 +0.03 (+0.06%)
As of 07/31/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Roundhill GLP-1 & Weight Loss ETF stock logo

Roundhill GLP-1 & Weight Loss ETF NASDAQ:OZEM

$31.78 -0.74 (-2.28%)
As of 07/31/2026 03:45 PM Eastern

The Roundhill GLP-1 & Weight Loss ETF (OZEM) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies from around the world involved in pharmaceutical drugs and supplements used for weight management. OZEM was launched on May 21, 2024 and is issued by Roundhill.

Amplify Weight Loss Drug & Treatment ETF stock logo

Amplify Weight Loss Drug & Treatment ETF NYSEARCA:THNR

$25.40 -0.46 (-1.78%)
As of 07/31/2026 04:10 PM Eastern

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas